These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 26562598)
41. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Binder T; Vavrinková B Neuro Endocrinol Lett; 2008 Feb; 29(1):80-6. PubMed ID: 18283247 [TBL] [Abstract][Full Text] [Related]
42. Matching of treatment-resistant heroin-dependent patients to medical prescription of heroin or oral methadone treatment: results from two randomized controlled trials. Blanken P; Hendriks VM; Koeter MW; van Ree JM; van den Brink W Addiction; 2005 Jan; 100(1):89-95. PubMed ID: 15598196 [TBL] [Abstract][Full Text] [Related]
43. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Hulse GK; Morris N; Arnold-Reed D; Tait RJ Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701 [TBL] [Abstract][Full Text] [Related]
44. Sustained incentive value of heroin-related cues in short- and long-term abstinent heroin users. Preller KH; Wagner M; Sulzbach C; Hoenig K; Neubauer J; Franke PE; Petrovsky N; Frommann I; Rehme AK; Quednow BB Eur Neuropsychopharmacol; 2013 Oct; 23(10):1270-9. PubMed ID: 23219936 [TBL] [Abstract][Full Text] [Related]
45. Patterns of major depression and drug-related problems amongst heroin users across 36 months. Darke S; Mills K; Teesson M; Ross J; Williamson A; Havard A Psychiatry Res; 2009 Mar; 166(1):7-14. PubMed ID: 19215987 [TBL] [Abstract][Full Text] [Related]
46. Rates and correlates of mortality amongst heroin users: findings from the Australian Treatment Outcome Study (ATOS), 2001-2009. Darke S; Mills KL; Ross J; Teesson M Drug Alcohol Depend; 2011 Jun; 115(3):190-5. PubMed ID: 21130585 [TBL] [Abstract][Full Text] [Related]
47. Long-term methadone maintenance reduces protracted symptoms of heroin abstinence and cue-induced craving in Chinese heroin abusers. Shi J; Zhao LY; Epstein DH; Zhang XL; Lu L Pharmacol Biochem Behav; 2007 May; 87(1):141-5. PubMed ID: 17532034 [TBL] [Abstract][Full Text] [Related]
48. Changes in route of drug administration among continuing heroin users: outcomes 1 year after intake to treatment. Gossop M; Stewart D; Marsden J; Kidd T; Strang J Addict Behav; 2004 Aug; 29(6):1085-94. PubMed ID: 15236809 [TBL] [Abstract][Full Text] [Related]
49. Outcome of heroin-dependent adolescents presenting for opiate substitution treatment. Smyth BP; Fagan J; Kernan K J Subst Abuse Treat; 2012 Jan; 42(1):35-44. PubMed ID: 21940134 [TBL] [Abstract][Full Text] [Related]
50. Static and dynamic predictors of criminal involvement among people with heroin dependence: findings from a 3-year longitudinal study. Marel C; Mills KL; Darke S; Ross J; Slade T; Burns L; Teesson M Drug Alcohol Depend; 2013 Dec; 133(2):600-6. PubMed ID: 24008022 [TBL] [Abstract][Full Text] [Related]
51. Risk adjustment of heroin treatment outcomes for comparative performance assessment in England. Marsden J; Eastwood B; Jones H; Bradbury C; Hickman M; Knight J; Randhawa K; White M; Addiction; 2012 Dec; 107(12):2161-72. PubMed ID: 22690731 [TBL] [Abstract][Full Text] [Related]
52. Changes and predictors of change in the physical health status of heroin users over 24 months. Williamson A; Darke S; Ross J; Teesson M Addiction; 2009 Mar; 104(3):465-70. PubMed ID: 19207357 [TBL] [Abstract][Full Text] [Related]
53. Can we predict retention in longitudinal studies of substance use? Findings from the Australian Treatment Outcome Study. Marel C; Mills K; Darke S; Ross J; Burns L; Teesson M Addict Behav; 2015 Dec; 51():38-43. PubMed ID: 26210911 [TBL] [Abstract][Full Text] [Related]
54. [Heroin-assisted treatment of opioid addicts in Switzerland from 1994-2001--utilisation and characteristics of admissions and discharges]. Gschwend P; Rehm J; Eschmann S; Uchtenhagen A Gesundheitswesen; 2003 Feb; 65(2):75-80. PubMed ID: 12632315 [TBL] [Abstract][Full Text] [Related]
55. Loss of treatment benefit when heroin-assisted treatment is stopped after 12 months. Demaret I; Quertemont E; Litran G; Magoga C; Deblire C; Dubois N; Charlier C; Lemaitre A; Ansseau M J Subst Abuse Treat; 2016 Oct; 69():72-5. PubMed ID: 27568513 [TBL] [Abstract][Full Text] [Related]
56. Years of potential life lost amongst heroin users in the Australian Treatment Outcome Study cohort, 2001-2015. Darke S; Marel C; Mills KL; Ross J; Slade T; Tessson M Drug Alcohol Depend; 2016 May; 162():206-10. PubMed ID: 27021806 [TBL] [Abstract][Full Text] [Related]
57. Disrupted integrity of white matter in heroin-addicted subjects at different abstinent time. Shen Y; Wang E; Wang X; Lou M J Addict Med; 2012 Jun; 6(2):172-6. PubMed ID: 22534416 [TBL] [Abstract][Full Text] [Related]
58. Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial. Oviedo-Joekes E; Guh D; Brissette S; Marchand K; MacDonald S; Lock K; Harrison S; Janmohamed A; Anis AH; Krausz M; Marsh DC; Schechter MT JAMA Psychiatry; 2016 May; 73(5):447-55. PubMed ID: 27049826 [TBL] [Abstract][Full Text] [Related]
59. Seven-year follow-up of heroin addicts: drug use and outcome. Stimson GV; Oppenheimer E; Thorley A Br Med J; 1978 May; 1(6121):1190-2. PubMed ID: 638690 [TBL] [Abstract][Full Text] [Related]
60. Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers. Woodcock EA; Lundahl LH; Greenwald MK Drug Alcohol Depend; 2015 Jan; 146():89-96. PubMed ID: 25479914 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]